Central neurocytoma

Last updated
Central neurocytoma
Neurocytome axiale.jpg
Axial T1-weighted gadolinium-enhanced MRI image showing an enhancing mass with cystic changes consistent with central neurocytoma in the right lateral ventricle.
Specialty Oncology, neurosurgery

Central neurocytoma (CNC) is an extremely rare, ordinarily benign intraventricular brain tumour that typically forms from the neuronal cells of the septum pellucidum. [1] The majority of central neurocytomas grow inwards into the ventricular system forming interventricular neurocytomas. This leads to two primary symptoms of CNCs, blurred vision and increased intracranial pressure. Treatment for a central neurocytoma typically involves surgical removal, with an approximate 1 in 5 chance of recurrence. [2] Central neurocytomas are classified as a grade II tumor under the World Health Organization's classification of tumors of the nervous system. [3]

Contents

Signs and symptoms

There is a wide range of symptoms that patients show. Symptoms can lie dormant, but come about due to Obstructive hydrocephalus. These symptoms include: [4]

In rare and extreme cases, more severe symptoms can be observed:

Pathology

Micrograph of a central neurocytoma. H&E stain. Central neurocytoma - high mag.jpg
Micrograph of a central neurocytoma. H&E stain.

On the macroscopic scale, CNC tumors are grayish in color, resembling the gray matter that comes with areas of hemorrhage. The tumors are soft, ovid, lobulated to nodular masses that are generally well circumscribed. When dissecting the tumor, scientists experienced some grittiness, which they attribute to the presence of calcification. [4]

Tumor samples stained using H&E stain and examined under the microscope revealed that CNC is a well-differentiated tumor with benign histological features. The tumor is composed of “uniform, small-to-medium-sized cells with rounded nuclei, finely stippled chromatin and inconspicuous nucleoli, along with scant cytoplasm.” CNC are characterized by perivascular pseudorosettes, circular/flower-like arrangements of cells with a small blood vessel at the centre, and polygonal small cells with a clear perinuclear halo, sometimes called the ‘fried egg’ appearance, and is clear or slightly eosinophilic. The main histomorphologic differential diagnosis is oligodendroglioma. While the tumor cells are dense in some areas, areas with anuclear, less dense tumor parts were dispersed throughout. The anuclear areas may have a fine fibrillary matrix, like that of neuropil regions. Long, thin-walled, capillary-sized vessels represent the vascularity of CNC. These vessels are arranged in a linear branching pattern, with an endocrine appearance. Thin-walled dilated vascular channels, as well as foci of calcification, were readily identified in many cases. [4]

Diagnosis

Treatment

The mainstay of treatment is surgical excision. [7] Two adjuvant therapeutic strategies are Stereotactic surgery (SRS) and fractionated convention radiotherapy (FCRT). Both are highly effective means of treatment. [8]

Surgery

Surgical excision of the central neurocytoma is the primary consensus among practicing physicians. The surgeons perform a craniotomy to remove the tumor. The ability to remove the tumor and to what extent it is removed is dependent upon the location of the tumor and surgeon experience and preference. The extent of the disease plays a large part in determining how effective the surgery will be. The main goal of a complete surgical resection, of the tumor, can also be hindered by the adherence of the tumor to adjoining structures or hemorrhages. [5] If there is a recurrence of the central neurocytoma, surgery is again the most notable treatment.

Radiotherapy

There is not much evidence supporting the claim that radiotherapy is a beneficial and effective means of treatment. Typically, radiotherapy is used postoperatively in respect to whether or not a partial or complete excision of the tumor has been accomplished. [9] The histopathological features of CNC, neuronal differentiation, low mitotic activity, absence of vascular endothelial proliferation, and tumor necrosis, suggest that the tumor may be resistant to ionizing radiation. However, when radiotherapy is used, whole brain or involved-field treatment is given. This method utilizes a standard fractionation schedule and a total tumor dose of 50-55 Gy. [5] Gamma knife surgery is a form of radiotherapy, more specifically radiosurgery that uses beams of gamma rays to deliver a certain dosage of radiation to the tumor. Gamma knife surgery is incredibly effective at treating neurocytoma and maintaining tumor control after the procedure when a complete excision has been performed. Some studies have found that the success rate of tumor control is around 90% after the first five years and 80% after the first ten years. [2] [10] Gamma knife surgery is the most recorded form of radiotherapy performed to treat remnants of the CNC tumor after surgery. [10]

Chemotherapy

Chemotherapy is typically limited to patients with recurrent central neurocytoma. The course of chemotherapy used for CNC is one of two platinum-based regimes. The two regimes are:

Because chemotherapy is used in rare cases there is still information to be gathered as to the efficacy of chemotherapy to treat benign CNC. Therefore, recommendations must be viewed as limited and preliminary. [5]

Outcome and recurrence

The majority of patients can be expected to be cured of their disease and become long-term survivors of central neurocytoma. As with any other type of tumor, there is a chance for recurrence. The chance of recurrence is approximately 20%. [2] Some factors that predict tumor recurrence and death due to progressive states of disease are high proliferative indices, early disease recurrence, and disseminated disease with or without the spread of disease through the cerebral spinal fluid. [5] Long-term follow up examinations are essential for the evaluation of the outcomes that each treatment brings about. It is also essential to identify possible recurrence of CN. It is recommended that a cranial MRI is performed between every 6–12 months. [2]

History

It was first described in 1982 by Hassoun. [11] Central neurocytomas are rare brain tumors that are located most of the times in the lateral ventricles near the Monro foramina. They were first discovered by Hassoun and co-workers in 1982, and were classified as grade II tumors. [12] In 1985, Wilson had also described a rare case of "differentiated neuroblastoma" in the lateral ventricle that resembles oligodendroglioma on light microscopy. However, the name central neurocytoma was given by Hassoun. [13]

Primary neuronal tumors occurring in the ventricular system were considered to be rare. Most cases described were of non-neuronal origin such as oligodendroglioma, ependymoma, meningioma, choroid plexus papilloma and giant cell. Neurocytomas were probably historically misdiagnosed as intraventricular oligondedronglioma or clear cell ependymoma prior to this. With its non-aggressive behavior the tumor has often been called "benign central neurocytoma". It is believed to occur in young adults from the neuronal cells of the septum pullicidum and the subependymal cells of the lateral ventricles. Most of the initial incidents reported in the lateral ventricle were benign. However, as more information was gathered the name benign central neurocytoma was started to be seen as a double misnomer because these tumors are not always benign nor centrally located. Many recent studies suggest that their location, biological potential and clinical behavior are observed be more variable than previously thought. Recent studies indicate their uncommon location, aggressive biological behavior and frequent recurrences following after surgical resection have generated significant interest in various treatment modalities and also in their terminology, lineage potential and molecular regulation. [13]

Epidemiology

CNC represent 0.1-0.5% of primary brain tumours. [14] [8] There is a genetic component to the formation of these tumors, causing a larger proportion of tumors to form in people of Asian descent than of other ethnic groups. [15] Central neurocytomas predominantly form in young adults, most commonly during the second or third decade of life. [16] There is no evidence that the sex of a person is a determinant in the frequency of central neurocytomas. [15]

Related Research Articles

<span class="mw-page-title-main">Brain tumor</span> Neoplasm in the brain

A brain tumor occurs when abnormal cells form within the brain. There are two main types of tumors: malignant (cancerous) tumors and benign (non-cancerous) tumors. These can be further classified as primary tumors, which start within the brain, and secondary tumors, which most commonly have spread from tumors located outside the brain, known as brain metastasis tumors. All types of brain tumors may produce symptoms that vary depending on the size of the tumor and the part of the brain that is involved. Where symptoms exist, they may include headaches, seizures, problems with vision, vomiting and mental changes. Other symptoms may include difficulty walking, speaking, with sensations, or unconsciousness.

<span class="mw-page-title-main">Basal-cell carcinoma</span> Most common type of skin cancer

Basal-cell carcinoma (BCC), also known as basal-cell cancer, basalioma or rodent ulcer, is the most common type of skin cancer. It often appears as a painless raised area of skin, which may be shiny with small blood vessels running over it. It may also present as a raised area with ulceration. Basal-cell cancer grows slowly and can damage the tissue around it, but it is unlikely to spread to distant areas or result in death.

<span class="mw-page-title-main">Vestibular schwannoma</span> Medical condition

A vestibular schwannoma (VS), also called acoustic neuroma, is a benign tumor that develops on the vestibulocochlear nerve that passes from the inner ear to the brain. The tumor originates when Schwann cells that form the insulating myelin sheath on the nerve malfunction. Normally, Schwann cells function beneficially to protect the nerves which transmit balance and sound information to the brain. However, sometimes a mutation in the tumor suppressor gene, NF2, located on chromosome 22, results in abnormal production of the cell protein named Merlin, and Schwann cells multiply to form a tumor. The tumor originates mostly on the vestibular division of the nerve rather than the cochlear division, but hearing as well as balance will be affected as the tumor enlarges.

<span class="mw-page-title-main">Oligodendroglioma</span> Medical condition

Oligodendrogliomas are a type of glioma that are believed to originate from the oligodendrocytes of the brain or from a glial precursor cell. They occur primarily in adults but are also found in children.

<span class="mw-page-title-main">Ependymoma</span> Medical condition

An ependymoma is a tumor that arises from the ependyma, a tissue of the central nervous system. Usually, in pediatric cases the location is intracranial, while in adults it is spinal. The common location of intracranial ependymomas is the fourth ventricle. Rarely, ependymomas can occur in the pelvic cavity.

<span class="mw-page-title-main">Meningioma</span> Type of tumor

Meningioma, also known as meningeal tumor, is typically a slow-growing tumor that forms from the meninges, the membranous layers surrounding the brain and spinal cord. Symptoms depend on the location and occur as a result of the tumor pressing on nearby tissue. Many cases never produce symptoms. Occasionally seizures, dementia, trouble talking, vision problems, one sided weakness, or loss of bladder control may occur.

<span class="mw-page-title-main">Radiosurgery</span> Surgical Specialty

Radiosurgery is surgery using radiation, that is, the destruction of precisely selected areas of tissue using ionizing radiation rather than excision with a blade. Like other forms of radiation therapy, it is usually used to treat cancer. Radiosurgery was originally defined by the Swedish neurosurgeon Lars Leksell as "a single high dose fraction of radiation, stereotactically directed to an intracranial region of interest".

<span class="mw-page-title-main">Benign tumor</span> Mass of cells which cannot spread throughout the body

A benign tumor is a mass of cells (tumor) that does not invade neighboring tissue or metastasize. Compared to malignant (cancerous) tumors, benign tumors generally have a slower growth rate. Benign tumors have relatively well differentiated cells. They are often surrounded by an outer surface or stay contained within the epithelium. Common examples of benign tumors include moles and uterine fibroids.

<span class="mw-page-title-main">Phyllodes tumor</span> Medical condition

Phyllodes tumors, are a rare type of biphasic fibroepithelial mass that form from the periductal stromal and epithelial cells of the breast. They account for less than 1% of all breast neoplasms. They were previously termed cystosarcoma phyllodes, coined by Johannes Müller in 1838, before being renamed to phyllodes tumor by the World Health Organization in 2003. Phullon, which means 'leaf' in Greek, describes the unique papillary projections characteristic of phyllodes tumors on histology. Diagnosis is made via a core-needle biopsy and treatment is typically surgical resection with wide margins (>1 cm), due to their propensity to recur.

<span class="mw-page-title-main">Craniopharyngioma</span> Medical condition

A craniopharyngioma is a rare type of brain tumor derived from pituitary gland embryonic tissue that occurs most commonly in children, but also affects adults. It may present at any age, even in the prenatal and neonatal periods, but peak incidence rates are childhood-onset at 5–14 years and adult-onset at 50–74 years. People may present with bitemporal inferior quadrantanopia leading to bitemporal hemianopsia, as the tumor may compress the optic chiasm. It has a point prevalence around two per 1,000,000. Craniopharyngiomas are distinct from Rathke's cleft tumours and intrasellar arachnoid cysts.

<span class="mw-page-title-main">Pleomorphic adenoma</span> Medical condition

Pleomorphic adenoma is a common benign salivary gland neoplasm characterised by neoplastic proliferation of epithelial (ductal) cells along with myoepithelial components, having a malignant potentiality. It is the most common type of salivary gland tumor and the most common tumor of the parotid gland. It derives its name from the architectural Pleomorphism seen by light microscopy. It is also known as "Mixed tumor, salivary gland type", which refers to its dual origin from epithelial and myoepithelial elements as opposed to its pleomorphic appearance.

<span class="mw-page-title-main">Schwannomatosis</span> Rare genetic disorder

Schwannomatosis is an extremely rare genetic disorder closely related to the more-common disorder neurofibromatosis (NF). Originally described in Japanese patients, it consists of multiple cutaneous schwannomas, central nervous system tumors, and other neurological complications, excluding hallmark signs of NF. The exact frequency of schwannomatosis cases is unknown, although some populations have noted frequencies as few as 1 case per 1.7 million people.

<span class="mw-page-title-main">Hemangioblastoma</span> Medical condition

Hemangioblastomas, or haemangioblastomas, are vascular tumors of the central nervous system that originate from the vascular system, usually during middle age. Sometimes, these tumors occur in other sites such as the spinal cord and retina. They may be associated with other diseases such as polycythemia, pancreatic cysts and Von Hippel–Lindau syndrome. Hemangioblastomas are most commonly composed of stromal cells in small blood vessels and usually occur in the cerebellum, brainstem or spinal cord. They are classed as grade I tumors under the World Health Organization's classification system.

<span class="mw-page-title-main">Choroid plexus papilloma</span> Medical condition

Choroid plexus papilloma, also known as papilloma of the choroid plexus, is a rare benign neuroepithelial intraventricular WHO grade I lesion found in the choroid plexus. It leads to increased cerebrospinal fluid production, thus causing increased intracranial pressure and hydrocephalus.

<span class="mw-page-title-main">Dysembryoplastic neuroepithelial tumour</span> Medical condition

Dysembryoplastic neuroepithelial tumour is a type of brain tumor. Most commonly found in the temporal lobe, DNTs have been classified as benign tumours. These are glioneuronal tumours comprising both glial and neuron cells and often have ties to focal cortical dysplasia.

<span class="mw-page-title-main">Esthesioneuroblastoma</span> Medical condition

Esthesioneuroblastoma is a rare cancer of the nasal cavity. Arising from the upper nasal tract, esthesioneuroblastoma is believed to originate from sensory neuroepithelial cells, also known as neuroectodermal olfactory cells.

<span class="mw-page-title-main">Sebaceous carcinoma</span> Medical condition

Sebaceous carcinoma, also known as sebaceous gland carcinoma (SGc), sebaceous cell carcinoma, and meibomian gland carcinoma is an uncommon malignant cutaneous tumor. Most are typically about 1.4 cm at presentation. SGc originates from sebaceous glands in the skin and, therefore, may originate anywhere in the body where these glands are found. SGc can be divided into 2 types: periocular and extraocular. The periocular region is rich in sebaceous glands making it a common site of origin. The cause of these lesions in the vast majority of cases is unknown. Occasional cases may be associated with Muir-Torre syndrome. SGc accounts for approximately 0.7% of all skin cancers, and the incidence of SGc is highest in Caucasian, Asian, and Indian populations. Due to the rarity of this tumor and variability in clinical and histological presentation, SGc is often misdiagnosed as an inflammatory condition or a more common neoplasm. SGc is commonly treated with wide local excision or Mohs micrographic surgery, and the relative survival rates at 5 and 10 years are 92.72 and 86.98%, respectively.

<span class="mw-page-title-main">Malignant chondroid syringoma</span> Type of skin cancer

A malignant chondroid syringoma is a very uncommon cutaneous (skin) condition characterised by an adnexal eccrine tumour.

Cardiac fibroma, also known as cardiac fibromatosis, cardiac fibrous hamartoma, fibroelastic hamartoma of heart and fibroma of heart is the second highest type of primary cardiac tumor seen in infants and children. This benign tumor made by connective tissue and fibroblast is largely observed in the ventricles of the heart. The left ventricle is the most common location of cardiac fibroma and accounts for approximately 57% of cardiac fibroma cases followed by the right ventricle with 27.5% of cases. Symptoms of the disease depend on the size of the tumor, its location relative to the conduction system, and whether it obstructs blood flow. Two-thirds of children with this tumor are asymptomatic, showing no signs and symptoms. Therefore the cause of cardiac fibroma is unexplained but has been associated with Gorlin Syndrome. Echocardiography is the primarily diagnostic method used to detect if an individual has cardiac fibroma. Resection of the tumor is recommended however heart transplantation is done if surgery is not possible. Overall prognosis of resection is favorable and the chance of recurrence is scarcely reported.

<span class="mw-page-title-main">Astroblastoma</span> Medical condition

Astroblastoma is a rare glial tumor derived from the astroblast, a type of cell that closely resembles spongioblastoma and astrocytes. Astroblastoma cells are most likely found in the supratentorial region of the brain that houses the cerebrum, an area responsible for all voluntary movements in the body. It also occurs significantly in the frontal lobe, parietal lobe, and temporal lobe, areas where movement, language creation, memory perception, and environmental surroundings are expressed. These tumors can be present in major brain areas not associated with the main cerebral hemispheres, including the cerebellum, optic nerve, cauda equina, hypothalamus, and brain stem.

References

  1. ↑ Kerkeni, A.; Ben Lakhdher, Z.; Rkhami, M.; Sebai, R.; Belguith, L.; Khaldi, M.; Ben Hamouda, M. (Oct 2010). "[Central neurocytoma: Study of 32 cases and review of the literature]". Neurochirurgie. 56 (5): 408–14. doi:10.1016/j.neuchi.2010.07.001. PMID   20692674.
  2. 1 2 3 4 Kim JW, Kim DG, Chung HT, Choi SH, Han JH, Park CK, Kim CY, Paek SH, Jung HW (December 2013). "Radiosurgery for central neurocytoma: long-term outcome and failure pattern". J. Neurooncol. 115 (3): 505–11. doi:10.1007/s11060-013-1253-9. PMID   24065568. S2CID   21557148.
  3. ↑ Louis David N.; Ohgaki Hiroko; Wiestler Otmar D.; Cavenee Webster K.; Burger Peter C.; Jouvet Anne; Scheithauer Bernd W.; Kleihues Paul (2007). "The 2007 WHO Classification of Tumours of the Central Nervous System". Acta Neuropathol. 114 (2): 97–109. doi:10.1007/s00401-007-0243-4. PMC   1929165 . PMID   17618441.
  4. 1 2 3 Li Y, Ye XF, Qian G, Yin Y, Pan QG (2012). "Pathologic features and clinical outcome of central neurocytoma: analysis of 15 cases". Chin J Cancer Res. 24 (4): 284–290. doi:10.1007/s11670-012-0265-x. PMC   3551323 . PMID   23358787.
  5. 1 2 3 4 5 Chamberlain, Marc C. Treatment of Central Neurocytoma. USC/Norris Cancer Center. Seattle Cancer Care Alliance. <https://www.seattlecca.org/client/Chamberlain_Treatment%20of%20Central%20Neurocytomas.pdf Archived 2014-03-24 at the Wayback Machine > Feb. 20 2014.
  6. ↑ Ouma, JR (2004). "Psychotic manifestations in brain tumour patients: 2 case reports from South Africa". Afr Health Sci. 4 (3): 190–194. PMC   2688330 . PMID   15687074.
  7. ↑ Schmidt, MH.; Gottfried, ON.; von Koch, CS.; Chang, SM.; McDermott, MW. (Feb 2004). "Central neurocytoma: a review". J Neurooncol. 66 (3): 377–84. doi:10.1023/b:neon.0000014541.87329.3b. PMID   15015671. S2CID   8320493.
  8. 1 2 Garcia RM.; Ivan ME.; Oh T.; Barani I.; Parsa AT. (2014). "Intraventricular neurocytomas: A systematic review of stereotactic radiosurgery and fractionated conventional radiotherapy for residual or recurrent tumors". Clinical Neurology and Neurosurgery. 117: 55–64. doi:10.1016/j.clineuro.2013.11.028. PMID   24438806. S2CID   23101170.
  9. ↑ Chen H, Zhou R, Liu J, Tang J (June 2012). "Central neurocytoma". J Clin Neurosci. 19 (6): 849–53. doi:10.1016/j.jocn.2011.06.038. PMID   22537657. S2CID   12995192.
  10. 1 2 Karlsson Bengt; Guo Wan-Yuo; Kejia Teo; Dinesh Nivedh; Pan David Hung-Chi; Jokura Hidefumi; Kawagishi Jun; van Eck Albertus; Horstmann Gerhard A.; Yeo Tseng Tsai; Yamamoto Masaaki (2012). "Gamma Knife surgery for central neurocytomas". J Neurosurg. 117 (Suppl): 96–101. doi: 10.3171/2012.6.GKS12214 . PMID   23205795.
  11. ↑ Hassoun, J.; Gambarelli, D.; Grisoli, F.; Pellet, W.; Salamon, G.; Pellissier, JF.; Toga, M. (1982). "Central neurocytoma. An electron-microscopic study of two cases". Acta Neuropathol. 56 (2): 151–6. doi:10.1007/bf00690587. PMID   7064664. S2CID   6524741.
  12. ↑ Qian H.; Lin S.; Zhang M.; Cao Y. (2012). "Surgical management of intraventricular central neurocytoma: 92 cases". Acta Neurochirurgica. 154 (11): 1951–60. doi:10.1007/s00701-012-1446-6. PMID   22941394. S2CID   11054237.
  13. 1 2 Choudhari K. A.; Kaliaperumal C.; Jain A.; Sarkar C.; Soo M.; Rades D.; Singh J. (2009). "Central neurocytoma: A multi-disciplinary review". British Journal of Neurosurgery. 23 (6): 585–595. doi:10.3109/02688690903254350. PMID   19922271. S2CID   1245015.
  14. ↑ Chuang, MT.; Lin, WC.; Tsai, HY.; Liu, GC.; Hu, SW.; Chiang, IC. (2005). "3-T proton magnetic resonance spectroscopy of central neurocytoma: 3 case reports and review of the literature". J Comput Assist Tomogr. 29 (5): 683–8. doi:10.1097/01.rct.0000171240.95430.29. PMID   16163043.
  15. 1 2 Sharma, Mehar Chand; Deb, Prabal; Sharma, Suash; Sarkar, Chitra (August 2006). "Neurocytoma: a comprehensive review". Neurosurgical Review. 29 (4): 270–285. doi:10.1007/s10143-006-0030-z. PMID   16941163. S2CID   7854296.
  16. ↑ Hassoun J, Soylemezoglu F, Gambarelli D, Figarella-Branger D, von Ammon K, Kleihues P (1993). "Central neurocytoma: a synopsis of clinical and histological features". Brain Pathology. 3 (3): 297–306. doi:10.1111/j.1750-3639.1993.tb00756.x. PMID   8293189. S2CID   19604295.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.